Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Rating of “Moderate Buy” from Analysts

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $40.00.

A number of analysts have commented on ZLAB shares. Citigroup reduced their price objective on Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Zacks Research raised Zai Lab from a “strong sell” rating to a “hold” rating in a research report on Tuesday. JPMorgan Chase & Co. reduced their target price on Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Wall Street Zen downgraded shares of Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings raised shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th.

Zai Lab Stock Performance

NASDAQ:ZLAB opened at $19.98 on Friday. The firm’s 50-day moving average is $18.68 and its 200-day moving average is $19.05. The company has a market cap of $2.27 billion, a price-to-earnings ratio of -12.33 and a beta of 0.76. Zai Lab has a 52-week low of $15.96 and a 52-week high of $41.20.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. The company had revenue of $99.61 million during the quarter. Equities analysts predict that Zai Lab will post -2.23 EPS for the current year.

Insider Activity

In related news, Director William Lis sold 7,040 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $18.09, for a total value of $127,353.60. Following the completion of the transaction, the director owned 50,437 shares of the company’s stock, valued at $912,405.33. This represents a 12.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Yajing Chen sold 2,264 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $17.46, for a total transaction of $39,529.44. Following the transaction, the chief financial officer owned 35,691 shares of the company’s stock, valued at approximately $623,164.86. This represents a 5.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 90,873 shares of company stock worth $1,730,096. Corporate insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On Zai Lab

A hedge fund recently raised its stake in Zai Lab stock. SG Americas Securities LLC lifted its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,396 shares of the company’s stock after buying an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. Institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.